Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sees Large Increase in Short Interest

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,900 shares, an increase of 118.5% from the September 15th total of 2,700 shares. Based on an average daily trading volume, of 113,200 shares, the days-to-cover ratio is currently 0.1 days.

Shionogi & Co., Ltd. Stock Performance

Shares of OTCMKTS:SGIOY traded down $0.01 on Friday, hitting $6.94. The company's stock had a trading volume of 83,568 shares, compared to its average volume of 84,809. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.37 and a current ratio of 5.86. The company has a market capitalization of $8.23 billion, a price-to-earnings ratio of 7.15, a price-to-earnings-growth ratio of 6.62 and a beta of 0.22. The stock's 50-day moving average is $10.46 and its two-hundred day moving average is $10.80. Shionogi & Co., Ltd. has a 12 month low of $6.22 and a 12 month high of $9.11.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last announced its earnings results on Monday, July 29th. The company reported $0.17 EPS for the quarter. The business had revenue of $625.99 million during the quarter. Shionogi & Co., Ltd. had a return on equity of 11.95% and a net margin of 35.53%. On average, equities research analysts forecast that Shionogi & Co., Ltd. will post 0.21 EPS for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.